Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

Table 2 Outcomes of novel agents and clinical trials in CRPC from ASCO-GU 2023

Dosing Regimens	Indication	Classification	Intervention	Regimen Backbone	Patient number	OS	PFS	ORR	PSA50	Clinical trail number	Reference
177Lu-J591	M0CRPC	RDC	177Lu-J591 + Keto + HC vs. 11In-J591(placebo) + Keto + HC	Keto + HC	55	-	18.67mon	-	82% (PSA90:50%)	NCT00859781	[2]
225Ac-J591	mCRPC	RDC	225Ac-J591 +Pemb + ARPI vs. Pemb + ARPI	Pemb + ARPI	76	-	33% > 6 mon	-	50%	NCT04946370	[3]
Lorigerlimab	mCRPC	DART	-	-	42	-	-	25.7%	28.6% (PSA90:21.4%)	NCT03761017	[5]
BPX-601	mCRPC	CAR-T	-	AR antagonist + Taxane	151	-	-	14.3%	42.9%	NCT02744287	[7]
Capivasertib	mCRPC	AKTi	Capivasertib + docetaxel vs. placebo + docetaxel	Docetaxel	790	31.5mon	7.03 mon	-	45%	NCT05348577	[9]

AKTi: Protein kinase inhibitor, AR: Androgen receptor, ARPI: Androgen receptor pathway inhibitor, CAR-T: Chimeric antigen receptor-T cell, DART: Dual antibody blockade in rare tumors, HC: hydrocortisone, Keto: ketoconazole,
mCRPC: Metastatic castration resistant prostate cancer, M0CRPC: non-metastatic castration resistant prostate cancer, mon: month, ORR: Objective response rate, OS: overall survival, PSA: prostate specific antigen,
PSA50: PSA decline ratio > 50%, PSA90: PSA decline ratio > 90%, PFS: progression free survival, Pemb: Pembrolizumab, RDC: Radionuclide drug conjugates

ISSN: 2162-3619